Verdict
Ferozsons Laboratories Limited (FEROZ) delivered a strong audited FY2026 earnings result, led by rapid expansion at BF Biosciences and better gross profitability. Consolidated revenue rose 27.1% to Rs23.958 billion, profit attributable to the owners increased 26.0% to Rs978.58 million, and earnings per share reached Rs22.51. The final cash dividend recommendation increased to Rs5.50 per share.
The quality of that growth was mixed rather than uniformly strong. Gross margin expanded, and finance cost fell sharply, but selling and distribution expenses grew much faster than revenue. Operating margin therefore narrowed. Cash conversion also weakened: inventory absorbed more than Rs2.1 billion, operating cash flow fell to Rs428.09 million, and capital expenditure substantially exceeded operating cash generation. The result is profitable and improving, but the next test is whether growth can be converted into cash without another large build-up in stock.
Results at a glance
The primary reporting basis used here is the Group’s audited consolidated financial statements for the year ended June 30, 2026. They include the parent, its 57.36%-owned subsidiary BF Biosciences Limited and its 98%-owned retail venture Farmacia. KPMG Taseer Hadi & Co. issued an unmodified opinion. Revenue recognition and inventory measurement were identified as key audit matters, which is relevant given the year’s sales growth and inventory increase.
Consolidated revenue increased to Rs23.958 billion from Rs18.857 billion. Gross profit rose 33.9% to Rs10.705 billion, and gross margin expanded to 44.68% from 42.41%, an improvement of about 2.27 percentage points. Profit from operations increased 16.2% to Rs2.475 billion, but operating margin eased to 10.33% from 11.29% because operating expenses, especially selling costs, grew faster than sales.
Finance cost declined 27.2% to Rs418.06 million. Profit before income tax, final tax and minimum-tax differential rose 32.3% to Rs2.057 billion. After a Rs40.78 million minimum-tax differential and Rs788.89 million income-tax charge, total group profit after tax increased 33.2% to Rs1.228 billion.
Of that group profit, Rs978.58 million was attributable to FEROZ shareholders and Rs249.15 million to non-controlling interests. This distinction matters: the Rs22.51 EPS is based on profit attributable to the owners, not total consolidated profit. The comparative EPS was Rs17.86.
The Board recommended a final cash dividend of Rs5.50 per share, up from Rs4.00, subject to shareholder approval at the October 28, 2026 annual general meeting. The payout will be recognized after approval rather than in the FY2026 statements.
AlphaGen model scores
These are AlphaGen model outputs, not figures reported by the company: Alpha QoQ Score: 75.50; TTM Performance Score: 84.07; 3Y Business Perf Score: 73.11; Sector Leadership Score: 52.43. The scores are presented only as model signals; the audited filing is the basis for the financial analysis.
What improved
BF Biosciences was the principal growth engine. Its total segment revenue rose 62.1% to Rs9.461 billion from Rs5.837 billion, while segment profit before income tax, final tax and minimum-tax differential increased 47.5% to Rs1.067 billion. Management separately reported BF Biosciences profit after tax of Rs632 million, up 41%. The subsidiary’s faster growth increased its importance to the consolidated result and explains much of the gap between the parent’s 14% sales growth and the Group’s 27% increase.
The parent business also advanced. Ferozsons’ segment revenue increased 13.7% to Rs15.757 billion and segment pre-tax profit rose 16.1% to Rs1.073 billion. Management says in-market generic sales grew 21%, primarily through volume, while institutional sales of generics and medical devices fell 2% because of constrained public-health budgets and procurement delays.
Margin improvement began above the operating line. Raw and packing materials consumed increased 28.1%, broadly in line with group revenue growth, while gross profit grew faster than sales. Management attributes the parent company’s gross-margin improvement to a change in sales mix and price increases in selected products. The consolidated statements do not quantify the separate price, volume and mix contributions, so the group-level margin bridge cannot be split more precisely.
Finance costs were another important support. They fell by Rs156.22 million to Rs418.06 million. Short-term conventional financing cost more than halved to Rs93.79 million, while Islamic short-term markup decreased to Rs159.44 million. Management attributes the overall reduction to lower average short-term borrowings and an approximately 300-basis-point reduction in the average SBP policy rate versus the prior year.
The revenue base remained predominantly domestic. Pakistan generated Rs22.879 billion, or about 95.5% of consolidated revenue, and grew 27.8%. Sri Lankan revenue rose to Rs418.45 million, while Afghanistan declined to Rs210.90 million. International diversification therefore remains modest despite selected export-market growth.
What weakened or needs attention
Selling and distribution expenses increased 40.7% to Rs6.970 billion, outpacing revenue growth by almost 14 percentage points. Salaries and benefits rose 35.4%, travelling and conveyance 47.9%, sales promotion 50.7%, and conferences, seminars and training 38.7%. Management links the increase to an expanded field force and enhanced field activity. These investments may support future sales, but in FY2026 they absorbed much of the gross-profit improvement.
Administrative expenses rose 29.6% to Rs1.169 billion, with salaries, travel, legal and professional charges, repairs and depreciation all higher. Other income fell 18.6% to Rs207.51 million because dividend income dropped sharply, even though realized gains on short-term investments increased. Consequently, operating profit grew only 16.2% despite 33.9% gross-profit growth.
Operating margin narrowed by about 0.96 percentage point when calculated from reported profit from operations, to 10.33% from 11.29%. This is the central earnings-quality tension: product and segment economics improved at the gross level, but the cost of commercial expansion prevented that improvement from fully reaching operating profit.
The stronger BF Biosciences contribution also means more profit belongs to outside shareholders. Non-controlling interests received Rs249.15 million of FY2026 profit, up from Rs145.17 million. Total group profit grew faster than profit attributable to FEROZ owners, which is why the 33.2% increase in consolidated profit translated into a smaller 26.0% increase in EPS.
Cash flow and balance-sheet quality
Cash generated before working-capital changes increased 12.0% to Rs3.625 billion. The improvement did not carry through to cash from operations because working capital absorbed Rs2.514 billion. Stock in trade used Rs2.127 billion, trade debts used Rs350.99 million, stores and spares used Rs216.66 million, and loans and advances used Rs137.56 million. Higher payables provided Rs464.02 million of partial relief.
After taxes, minimum tax, statutory funds and long-term deposits, net operating cash fell 70.2% to Rs428.09 million from Rs1.436 billion. Acquisition of property, plant and equipment was Rs1.178 billion. Subtracting that capital expenditure from operating cash produces a negative Rs749.60 million before intangibles and investment movements. This is an analytical cash-generation measure, not a company-reported free-cash-flow figure.
The reported investing cash inflow of Rs269.18 million should therefore be interpreted carefully. It was enabled by a Rs1.387 billion net release from short-term investments; it did not mean normal operations funded all investment. Cash and bank balances declined 7.3% to Rs642.11 million, and cash equivalents after bank-overdraft-type short-term borrowings moved to negative Rs98.81 million from positive Rs137.38 million.
Inventory increased 31.5% to Rs8.680 billion, faster than revenue, and represented 62% of current assets. Trade debts rose a more moderate 12.5% to Rs2.589 billion. The audited current ratio slipped to about 1.87 times from 1.94 times. Interest-bearing borrowings were broadly stable at roughly Rs4.25 billion, but their mix shifted toward short-term borrowing as long-term balances declined.
Capital investment is nevertheless strategically relevant. The parent invested Rs575 million mainly in a blistering machine and modernization of its Nowshera production facility. Across the consolidated cash flow, property, plant and equipment purchases were Rs1.178 billion. The annual report also describes more than Rs4 billion of cumulative technology upgrades at BF Biosciences, but does not disclose a quantified FY2027 revenue or margin return from those projects.
Historical and sector context
The longer trend is favorable but less linear than the headline growth rate suggests. Consolidated revenue has risen from Rs8.879 billion in FY2021 to Rs23.958 billion in FY2026. Gross margin improved from 41.28% in FY2021 and 37.19% in FY2023 to 44.68% in FY2026. However, operating margin remains below the 17.43% recorded in FY2021 because the commercial and administrative cost base has expanded.
Official Pakistan Bureau of Statistics data show pharmaceutical large-scale manufacturing output declined 8.87% in July-June FY2026. FEROZ’s 27.1% consolidated revenue increase therefore materially outpaced the domestic production index. This does not by itself prove market-share gains because FEROZ includes imported products, distribution activity and price effects, but it does show company growth was not simply a reflection of broad sector production growth.
Drug pricing remains a decision-relevant constraint. DRAP stated in March 2026 that essential medicines had not received a new general price increase and manufacturers could not unilaterally raise prices for products on the National Essential Medicines List. That makes product mix, approved pricing, volume and cost control important. The company’s own report identifies regulated pricing, imported active ingredients, foreign exchange and supply-chain disruption as material risks.
The financing backdrop also changed late in the year. Although FEROZ benefited from a lower average policy rate, the State Bank raised the policy rate by 100 basis points to 11.5% effective April 28, 2026. Lower FY2026 finance cost is reported fact; assuming the same percentage reduction in FY2027 would be speculative without lower average borrowings or another favorable rate shift.
What to monitor next
First, monitor BF Biosciences revenue and pre-tax margin. It is now the fastest-growing segment, but segment pre-tax profit rose more slowly than revenue in FY2026. Continued scale should eventually improve, rather than dilute, segment profitability.
Second, track group selling and distribution costs relative to revenue. Field-force expansion, promotion and conferences can build demand, but a durable operating-margin recovery requires these expenses to grow more slowly than gross profit.
Third, watch inventory and operating cash conversion. The critical questions are whether the FY2026 stock build supports forthcoming sales, whether inventory provisions remain controlled, and whether operating cash flow recovers toward profit after tax. Revenue recognition and inventory were also the auditor’s key audit matters, reinforcing their importance.
Fourth, separate parent and subsidiary economics. Consolidated profit includes non-controlling interests, while FEROZ EPS reflects only the owners’ share. Fifth, monitor institutional sales, which remained constrained by public-sector budgets and procurement timing. Sixth, test whether lower finance cost survives the tighter policy-rate environment.
Bottom line
FEROZ’s FY2026 result passes the core quality test: identity, period, consolidated basis, earnings and comparisons are publicly verified, and the principal movements are explained by the audited filing. BF Biosciences, stronger in-market generic volumes, better mix and lower finance costs produced meaningful earnings growth. The main weakness is cash conversion, not reported profitability.
The next phase of the story depends on converting the expanded commercial platform and inventory base into cash-generating sales. If selling-cost growth moderates and inventory turns improve, the FY2026 gross-margin gain can reach operating profit more fully. If stock continues to rise and field expenses remain elevated, earnings may grow without a comparable improvement in liquidity. This is an operating assessment, not investment advice.
Sources
Primary audited filing: Ferozsons Laboratories Limited Annual Report 2026 (PSX PDF)
Exchange record: Pakistan Stock Exchange — FEROZ company page
Company filing hub: Ferozsons Laboratories — Investor Information
Industry context: Pakistan Bureau of Statistics — June 2026 LSM report
Drug-pricing context: Government of Pakistan — DRAP clarification, March 29, 2026
Interest-rate context: State Bank of Pakistan Monetary Policy Statement, April 27, 2026